Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Only eight days remain until Arena Pharmaceuticals’ FDA PDUFA date for its potentially huge obesity drug, Lorcaserin, possibly causing investors to feel more confident that a delay lasting 3-6 months. It should be noted that the company’s rival, Vivus, Inc.(NASDAQ:VVUS), announced a three month PDUFA delay for its drug Qnexa only eight days before its scheduled PDUFA date.
